- Home
- UFCS vs XERS Comparison
UFCS vs XERS Comparison
Compare UFCS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | XERS |
|---|---|---|
| Founded | 1946 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.4M | 1.0B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UFCS | XERS |
|---|---|---|
| Price | $48.23 | $6.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $40.50 | $10.83 |
| AVG Volume (30 Days) | 85.8K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | 87.45 | ★ 100.00 |
| EPS | ★ 1.15 | 0.01 |
| Revenue | ★ $1,386,412,000.00 | $49,590,000.00 |
| Revenue This Year | $11.80 | $34.37 |
| Revenue Next Year | $8.77 | $22.86 |
| P/E Ratio | $40.72 | ★ N/A |
| Revenue Growth | 10.62 | ★ 142.67 |
| 52 Week Low | $25.81 | $4.30 |
| 52 Week High | $47.27 | $10.08 |
Technical Indicators
Market Signals| Indicator | UFCS | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 78.74 | 57.52 |
| Support Level | $36.27 | $6.26 |
| Resistance Level | N/A | $7.21 |
| Average True Range (ATR) | 1.39 | 0.27 |
| MACD | 0.72 | 0.04 |
| Stochastic Oscillator | 93.05 | 50.21 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.